What is Atlas Genetics?
Atlas Genetics operates at the intersection of biotechnology and point-of-care diagnostics. The company is dedicated to revolutionizing patient access to rapid, accurate testing through its specialized molecular diagnostic platforms. By streamlining the diagnostic workflow for infectious diseases, the firm enables healthcare providers to deliver immediate treatment, thereby reducing the traditional barriers to care. This market position is supported by a robust intellectual property portfolio and strategic partnerships with major pharmaceutical and medical technology organizations, ensuring that their diagnostic solutions remain at the forefront of clinical efficiency and patient-centric care.
How much funding has Atlas Genetics raised?
Atlas Genetics has raised a total of $85.9M across 4 funding rounds:
Series A
$2.5M
Series B
$28.4M
Series C
$20M
Series D
$35M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2014): $28.4M led by Novartis, Consort Medical - UK, YFM Equity Partners, Life Sciences Partners, Johnson & Johnson Development Corporation, and BB Biotech Ventures
Series C (2015): $20M supported by RMI Partners, Novartis, RusnanoMedInvest, Life Sciences Partners, Consort Medical - UK, BB Biotech Ventures, and Johnson & Johnson
Series D (2017): $35M featuring Technology Venture Partners, RMI Partners, Novartis Venture Fund, Wondfo Biotech, Johnson & Johnson, Consort Medical - UK, and BB Biotech Ventures
Key Investors in Atlas Genetics
Novartis
Novartis is a global pharmaceutical manufacturer specializing in the research and development of innovative medications and healthcare solutions across multiple therapeutic areas.
Johnson & Johnson
Johnson & Johnson is a multinational healthcare corporation that develops pharmaceuticals and medical technologies, focusing on oncology, immunology, and cardiovascular care.
BB Biotech Ventures
BB Biotech Ventures is a healthcare-dedicated venture capital firm that manages funds focused on private companies developing drugs, medical devices, and healthcare services.
What's next for Atlas Genetics?
With the infusion of capital from its latest financing round, Atlas Genetics is well-positioned to accelerate the commercial deployment of its diagnostic technologies. The strategic focus will likely shift toward expanding the reach of its testing platforms into new clinical environments and enhancing the diagnostic menu to address a broader spectrum of health conditions. As the company continues to leverage its deep-rooted relationships with global healthcare conglomerates, it is expected to prioritize operational scaling and the integration of its molecular testing solutions into standard clinical practice, further solidifying its influence in the global diagnostics landscape.
See full Atlas Genetics company page
